General News Oxurion nv Enrolls First Patient in Phase 1 Clinical Trial Evaluating THR-687, a Novel Pan-RGD Integrin Antagonist, for Treatment of Diabetic Macular Edema (DME) EN September 20, 2018
General News Oxurion Enrolls First Patient in Phase 2 Clinical Study Evaluating THR-317 (anti-PlGF) for treatment of Idiopathic Macular Telangiectasia Type 1 (MacTel 1) EN September 20, 2018
General News Oxurion NV to present further scientific findings supporting therapeutic potential of THR-317 and THR-687 as promising new therapies for Diabetic Eye Disease at upcoming EURETINA 2018 in Vienna, Austria EN September 17, 2018
General News Oxurion NV Announces New Euronext Brussels Stock Ticker “OXUR” and Launch of New Website EN September 10, 2018
General News ThromboGenics Reports Day 150 Topline Data from its Phase 1/2 Clinical Study evaluating THR-317 (anti-PlGF) for the Treatment of Diabetic Macular Edema (DME) EN July 19, 2018
General News ThromboGenics Partners with Prevent Blindness at 2018 Focus on Eye Health National Summit in Washington DC EN June 21, 2018
General News ThromboGenics Enrolls First Patient in Phase 1 Clinical Study Evaluating THR-149, a plasma kallikrein inhibitor, for treatment of Diabetic Macular Edema (DME) EN May 25, 2018
General News ThromboGenics to present a preclinical overview of its two most advanced diabetic eye disease clinical candidates, THR-317 and THR-149, at EASDec 2018 EN May 23, 2018
General News ThromboGenics Presenting Industry Expertise and Developments at Bio€quity Europe and Knowledge for Growth meetings in Ghent, Belgium EN May 14, 2018
General News ThromboGenics Initiates Phase 2 Clinical Study Evaluating anti-PlGF (THR-317) in combo with anti-VEGF (ranibizumab) for treatment of DME EN April 27, 2018
General News ThromboGenics announces publication in The Journal of Medicinal Chemistry of preclinical data supporting therapeutic potential of THR-149 EN April 6, 2018
General News ThromboGenics Reports Initial Data from its Clinical Study evaluating THR-317 for the Treatment of Diabetic Macular Edema (DME) EN April 4, 2018
General News Regulated Disclosure in accordance with Belgian Law of 2 May 2007 EN NL January 30, 2018
General News Regulated ThromboGenics – Patient Enrolment in Phase II CIRCLE Study Evaluating THR-409 (ocriplasmin) for Non-Proliferative Diabetic Retinopathy Discontinued due to Slow Recruitment Rate EN December 8, 2017
